FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912883859> ?p ?o ?g. }

• W2912883859 endingPage "1060" @default.
• W2912883859 startingPage "1052" @default.
• W2912883859 abstract "Background Antibody drug conjugates (ADC) offer the potential of maximizing efficacy while minimizing systemic toxicity. ASG-5ME, an SLC44A4-targeting antibody carrying monomethyl auristatin E (MMAE), a microtubule-disrupting agent, was investigated in men with metastatic castration resistant prostate cancer. Methods The primary objective of this phase I study was to determine maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives were safety, antitumor activity, pharmacokinetic properties, immunogenicity, and the detection of SLC44A4 on circulating tumor cells. Patients (pts) were treated among 7 dose levels every 21 days. A dose expansion phase enrolled 20 additional pts. at the MTD. Results Twenty-six and 20 pts. were treated in dose escalation and dose expansion cohorts respectively. The MTD was 2.7 mg/kg. Dose-limiting toxicities occurred in 4 pts.: grade 3 fatigue (n = 1); grade 3 abdominal pain, diarrhea and fatigue (n = 1); grade 4 neutropenia and hyponatremia and grade 3 maculopapular rash, constipation and hypoxia (n = 1); grade 3 troponin elevation without cardiac sequelae (n = 1). Fatigue and diarrhea were the most prevalent adverse events (AEs) across all cycles. Two grade 5 AEs occurred in the dose expansion cohort, each after 1 dose: 1 pt. developed grade 3 hyperglycemia, renal insufficiency and leukopenia; 1 pt. developed grade 3 hyperglycemia complicated by bacteremia. Free MMAE levels did not accumulate with repeat dosing. Of evaluable pts., 52% had either stable disease or a partial response. Conclusions Further development of ASG-5ME is not being pursued due to its narrow therapeutic index. Some toxicities were potentially related to on-target effects on normal tissue expressing the SLC44A4 protein. However, other toxicities were consistent with studies of previous MMAE-containing ADCs. Unconjugated MMAE is a less likely etiology based on prior data." @default.
• W2912883859 created "2019-02-21" @default.
• W2912883859 creator A5000198604 @default.
• W2912883859 creator A5002358672 @default.
• W2912883859 creator A5012074439 @default.
• W2912883859 creator A5014874649 @default.
• W2912883859 creator A5017288060 @default.
• W2912883859 creator A5018645768 @default.
• W2912883859 creator A5019370931 @default.
• W2912883859 creator A5028015088 @default.
• W2912883859 creator A5032001706 @default.
• W2912883859 creator A5036310901 @default.
• W2912883859 creator A5038771442 @default.
• W2912883859 creator A5039147214 @default.
• W2912883859 creator A5043124894 @default.
• W2912883859 creator A5047583995 @default.
• W2912883859 date "2019-02-06" @default.
• W2912883859 modified "2023-10-01" @default.
• W2912883859 title "A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer" @default.
• W2912883859 cites W1984335567 @default.
• W2912883859 cites W2011118089 @default.
• W2912883859 cites W2055342008 @default.
• W2912883859 cites W2075689961 @default.
• W2912883859 cites W2099367648 @default.
• W2912883859 cites W2113413385 @default.
• W2912883859 cites W2120292596 @default.
• W2912883859 cites W2120599736 @default.
• W2912883859 cites W2123526148 @default.
• W2912883859 cites W2138421719 @default.
• W2912883859 cites W2142709610 @default.
• W2912883859 cites W2148820240 @default.
• W2912883859 cites W2148998801 @default.
• W2912883859 cites W2159967578 @default.
• W2912883859 cites W2163470211 @default.
• W2912883859 cites W2167331614 @default.
• W2912883859 cites W2177243316 @default.
• W2912883859 cites W2300283319 @default.
• W2912883859 cites W2513596443 @default.
• W2912883859 doi "https://doi.org/10.1007/s10637-019-00731-5" @default.
• W2912883859 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6684870" @default.
• W2912883859 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30725389" @default.
• W2912883859 hasPublicationYear "2019" @default.
• W2912883859 type Work @default.
• W2912883859 sameAs 2912883859 @default.
• W2912883859 citedByCount "10" @default.
• W2912883859 countsByYear W29128838592019 @default.
• W2912883859 countsByYear W29128838592020 @default.
• W2912883859 countsByYear W29128838592022 @default.
• W2912883859 countsByYear W29128838592023 @default.
• W2912883859 crossrefType "journal-article" @default.
• W2912883859 hasAuthorship W2912883859A5000198604 @default.
• W2912883859 hasAuthorship W2912883859A5002358672 @default.
• W2912883859 hasAuthorship W2912883859A5012074439 @default.
• W2912883859 hasAuthorship W2912883859A5014874649 @default.
• W2912883859 hasAuthorship W2912883859A5017288060 @default.
• W2912883859 hasAuthorship W2912883859A5018645768 @default.
• W2912883859 hasAuthorship W2912883859A5019370931 @default.
• W2912883859 hasAuthorship W2912883859A5028015088 @default.
• W2912883859 hasAuthorship W2912883859A5032001706 @default.
• W2912883859 hasAuthorship W2912883859A5036310901 @default.
• W2912883859 hasAuthorship W2912883859A5038771442 @default.
• W2912883859 hasAuthorship W2912883859A5039147214 @default.
• W2912883859 hasAuthorship W2912883859A5043124894 @default.
• W2912883859 hasAuthorship W2912883859A5047583995 @default.
• W2912883859 hasBestOaLocation W29128838592 @default.
• W2912883859 hasConcept C112705442 @default.
• W2912883859 hasConcept C121608353 @default.
• W2912883859 hasConcept C126322002 @default.
• W2912883859 hasConcept C197934379 @default.
• W2912883859 hasConcept C2777063308 @default.
• W2912883859 hasConcept C2778375690 @default.
• W2912883859 hasConcept C2780192828 @default.
• W2912883859 hasConcept C2780873365 @default.
• W2912883859 hasConcept C29730261 @default.
• W2912883859 hasConcept C71924100 @default.
• W2912883859 hasConcept C90924648 @default.
• W2912883859 hasConcept C98274493 @default.
• W2912883859 hasConceptScore W2912883859C112705442 @default.
• W2912883859 hasConceptScore W2912883859C121608353 @default.
• W2912883859 hasConceptScore W2912883859C126322002 @default.
• W2912883859 hasConceptScore W2912883859C197934379 @default.
• W2912883859 hasConceptScore W2912883859C2777063308 @default.
• W2912883859 hasConceptScore W2912883859C2778375690 @default.
• W2912883859 hasConceptScore W2912883859C2780192828 @default.
• W2912883859 hasConceptScore W2912883859C2780873365 @default.
• W2912883859 hasConceptScore W2912883859C29730261 @default.
• W2912883859 hasConceptScore W2912883859C71924100 @default.
• W2912883859 hasConceptScore W2912883859C90924648 @default.
• W2912883859 hasConceptScore W2912883859C98274493 @default.
• W2912883859 hasFunder F4320337351 @default.
• W2912883859 hasIssue "5" @default.
• W2912883859 hasLocation W29128838591 @default.
• W2912883859 hasLocation W29128838592 @default.
• W2912883859 hasOpenAccess W2912883859 @default.
• W2912883859 hasPrimaryLocation W29128838591 @default.
• W2912883859 hasRelatedWork W1833952634 @default.
• W2912883859 hasRelatedWork W2037576960 @default.
• W2912883859 hasRelatedWork W2056387366 @default.

• next